Google
BCTX Stock Price & Analysis — Briacell Therapeutics Corp (Healthcare >> Biotechnology)
BCTX FAQ
What is BCTX's ROE?
Briacell Therapeutics Corp reports a Return on Equity (ROE) of -154.06%.
What is BCTX's dividend yield?
Briacell Therapeutics Corp offers a dividend yield of 0.00%.
What is BCTX's Quality Score?
Our AI rates BCTX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BCTX?
Our AI Timing Score for BCTX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BCTX belong to?
Briacell Therapeutics Corp is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
BCTX AI Analysis Summary
Our AI summary for BCTX: Briacell Therapeutics Corp (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -154.06%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.50
Price
0.13
(3.86%)
Day Change
|
|
|---|
BCTX, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 48 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.50 |
| PBV / Sector |
1.25 / 44,105.10
GOOD
|
| Earning Per Share | -4.42 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.42 M
GREAT
|
| Average 1W Daily Value |
0.43 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:41 |
| Symbol | BCTX |
| Name | BRIACELL THERAPEUTICS CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 8.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 29.32 / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Phone: 604 921 1810
Website: https://briacell.com
Sector: Healthcare >> Biotechnology
Description: BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap